WhatsApp
backNews Article

Viyash Scientific Posts 17.8% Revenue Growth and 49.4% Higher Profit After Tax in H1 FY27 with BioForLife Acquisition

The company reinforces companion animal business and expands R&D, manufacturing, and API capacity after acquiring Italy-based BioForLife in October 2026

Viyash Scientific Limited announced a 17.8% year-on-year revenue increase to ₹19,343 million and a 49.4% rise in profit after tax to ₹1,639 million for H1 FY27. The company completed the acquisition of BioForLife in Italy to enhance its companion animal segment, while continuing investments in oncology, manufacturing, and API expansion.

6 days ago|VIYASH-1.12%
Viyash Scientific LimitedVIYASHInvestor Presentation

Viyash Scientific Limited

Investor Presentation

Viyash Scientific Limited reported a 17.8% increase in revenues to ₹19,343 million and a 49.4% increase in profit after tax to ₹1,639 million for the first half of fiscal year 2027. The company completed the acquisition of BioForLife in Italy, strengthening its companion animal business segment.

Revenue for Q2 FY27 reached ₹9,879 million, a 16.2% increase from Q2 FY26, with EBITDA rising 10.3% to ₹2,077 million. EBITDA margin stood at 21.0% for the quarter, slightly down 110 basis points year-over-year.

The net debt to last twelve months EBITDA ratio improved to 0.0x in H1 FY27 from 0.7x in H1 FY26, reflecting the company’s strengthened balance sheet with net debt decreasing to ₹261 million versus ₹4,095 million a year earlier.

The acquisition of BioForLife, completed on October 1, 2026, provides an established portfolio of 85-90 companion animal products and enhances Viyash Scientific’s presence in the Italian companion animal market with 85% veterinary clinic coverage by the acquired salesforce.

The company increased investments in research and development focusing on companion animals and oncology capabilities, alongside expanding in-house companion animal manufacturing and API capacities to meet growing customer demand.

For H1 FY27, the company reported EBITDA before ESOP cost of ₹4,124 million, up 29.9% year-over-year, while adjusted EBITDA margins improved by 200 basis points to 21.3%. ESOP costs rose to ₹667 million due to incremental grants following amalgamation.

Highlights

  • H1 FY27 revenue increased 17.8% year-on-year to ₹19,343 million
  • Profit after tax rose 49.4% to ₹1,639 million in H1 FY27
  • EBITDA of ₹4,124 million in H1 FY27, up 29.9% year-on-year
  • Net debt reduced significantly to ₹261 million at H1 FY27 end
  • Acquisition of BioForLife in Italy completed October 1, 2026, expanding companion animal portfolio
  • BioForLife provides 85-90 companion animal products and 85% vet clinic coverage in Italy salesforce coverage of 85% in Italy served by BioForLife’s sales team

Key Data Snapshot

H1 FY27 Revenue₹19,343 Million
H1 FY27 Profit After Tax₹1,639 Million
H1 FY27 EBITDA (before ESOP cost)₹4,124 Million
Q2 FY27 Revenue₹9,879 Million
Q2 FY27 EBITDA (before ESOP cost)₹2,077 Million
Q2 FY27 EBITDA Margin21.0 %
Net Debt at H1 FY27₹261 Million
Net Debt to LTM EBITDA Ratio at H1 FY270.0x
ESOP Cost for H1 FY27₹667 Million
BioForLife Acquisition Completion Date1 October 2026
Number of Companion Animal Products from BioForLife85-90
Veterinary Clinic Coverage by BioForLife Sales Team in Italy85 %

What happened

  • Viyash Scientific reported a 17.8% increase in revenue and a 49.4% rise in profit after tax for H1 FY27 compared to H1 FY26.
  • The company’s EBITDA before ESOP cost grew 29.9% year-on-year to ₹4,124 million with an improved margin of 21.3%.
  • Net debt significantly decreased to ₹261 million at the end of H1 FY27 from ₹4,095 million in the previous year.
  • The acquisition of BioForLife in Italy was completed on October 1, 2026, broadening Viyash’s companion animal portfolio and market presence.

Key details

  • Q2 FY27 revenue increased 16.2% year-on-year to ₹9,879 million, with EBITDA up 10.3% to ₹2,077 million.
  • ESOP costs increased to ₹667 million in H1 FY27 due to incremental grants connected to amalgamation.
  • BioForLife offers 85-90 companion animal products and access to a well-covered Italian veterinary salesforce.
  • Viyash is investing in oncology capabilities, in-house companion animal manufacturing and expanding API capacity to cater to customer demand.

Financial performance

  • Revenue for H1 FY27 was ₹19,343 million, up 17.8% compared to ₹16,419 million in H1 FY26.
  • Profit after tax for H1 FY27 was ₹1,639 million versus ₹1,098 million in H1 FY26.
  • EBITDA margin improved by 200 basis points to 21.3% for H1 FY27.
  • Net debt to last twelve months EBITDA ratio improved to 0.0x from 0.7x year-over-year, reflecting lower leverage.

Business impact

  • The BioForLife acquisition enhances Viyash’s companion animal product range and provides strong market access in Italy.
  • Increased R&D investment supports new product development in companion animals and oncology.
  • Expansion of manufacturing and API production capacity aligns with anticipated customer demand growth.
  • The company maintains focus on disciplined execution, innovation-led growth, and sustainable value creation.

Regulatory and governance context

  • The investor presentation was filed on November 13, 2026, pursuant to SEBI Regulation 30 disclosure requirements.
  • The acquisition agreement (SPA) for BioForLife was executed on July 21, 2026, with completion occurring October 1, 2026.

More News on Investor Presentation

View all

Latest corporate announcements and market updates in Investor Presentation.

View all news
Viyash Scientific Posts 17.8% Revenue Growth and 49.4% | Stockk News